Estimation of Myeloperoxidase and Some Biochemical Parameters in Patients with Chronic Kidney Disease

Background: Chronic kidney disease (CKD) is a complex disease impacting more than twenty million individuals in the United States. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease. CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality. A multidisciplinary approach is required to accomplish this goal. Aim: The aim of the study to estimation myeloperoxidase activity in CKD patients and its association with other biochemical parameters (Creatinine and eGFR). Patients and Methods: A Case-control study is carried out Baghdad in the Imamian Kadhimian Medical City and Al- Karamah Teaching Hospital between August 2022 and March 2023. The number of CKD male under study was 60 male whose ages were between 25 to 50 years old. In addition, the control group consisted of 30 healthy volunteer males aged between 25 to 50 years and they did not have any diseases. Blood samples collected from each male for measurement of Myeloperoxidase (MPO) by Enzyme linked immunosorbent assay (ELISA), measure of serum creatinine by Abbott c4000 clinical chemistry analyzer and eGFR by MDRD equation. The study showed that the reduced mean level of myeloperoxidase (p value <0.001) in patients group compared with control group, (19.9±6.82 ng/ml) and (42.4±4.98 ng/ml) respectively. Our study revealed that with increasing CKD stage, the myeloperoxidase levels decrease. Also, the elevated mean level of creatinine was 7.47±2.8 mg/dl in patient group was highly significant than control group 0.84±0.158 mg/dl p value <0.001. The decrease mean of GFR was 9.42±3.53 in patients compared with controls 109±22.6 with high statistically significance (p<0.001). The study found a positive correlation between MPO and GFR and negative correlation of serum myeloperoxidase with serum creatinine level in CKD patients.